AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10196463 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired phosphorylation of cyclic AMP response element binding protein (pCREB) in DAT
Number of subjects: 0
Study 10196463 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-DAT)
Number of subjects: 0
Study 7495918 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration phase with rewards based on right minus left alpha differences exceeding baseline mean plus 0.85 SD (p = 0.20)
Number of subjects: 13
Study 7495918 — intervention group
Group type: EXPERIMENTAL
Intervention: Training phase with rewards based on hit rates
Number of subjects: 13
Study 2405531 — intervention group
Group type: EXPERIMENTAL
Intervention: 145 cGy n gamma x twelve fractions, three fractions per week (total 17.4 Gy n gamma)
Number of subjects: 28
Study 2405531 — intervention group
Group type: EXPERIMENTAL
Intervention: 155 cGy n gamma x twelve fractions, three fractions per week (total 18.6 Gy n gamma)
Number of subjects: 28
Study 7009441 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen stepwise 150, 200, and 250 mg/day
Number of subjects: 36
Study 7009441 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen 350, 400, and 450 mg/day
Number of subjects: 36
Study 7009441 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 100 mg/day
Number of subjects: 36
Study 7009441 — intervention group
Group type: COMPARATOR
Intervention: Carprofen low dosage regimen
Number of subjects: 36
Study 31196016 — intervention group
Group type: EXPERIMENTAL
Intervention: Carglumic acid (50 mg/kg/day) plus standard therapy (protein-restricted diet, L-carnitine, and metronidazole)
Number of subjects: 0
Study 31196016 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone (protein-restricted diet, L-carnitine, and metronidazole)
Number of subjects: 0
Study 28926579 — intervention group
Group type: COMPARATOR
Intervention: LBC screening
Number of subjects: 4995
Study 28926579 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV+LBC triage
Number of subjects: 4995
Study 28926579 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV+DS triage
Number of subjects: 4995
Study 25550147 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA, 10 + 10') with 10 min interval
Number of subjects: 15
Study 25550147 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA, 10 + 10') with 30 min interval
Number of subjects: 15
Study 25550147 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA, 10 + 10') with 60 min interval
Number of subjects: 15
Study 25550147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS with 10 min interval
Number of subjects: 15
Study 23452586 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron- and zinc-fortified infant cereals
Number of subjects: 45
Study 23452586 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-only fortified infant cereals
Number of subjects: 45
Study 23452586 — intervention group
Group type: COMPARATOR
Intervention: Commercially available pureed meats
Number of subjects: 45
Study 23452586 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric microbiota in the meat FG
Number of subjects: 45
Study 21071558 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO therapy (50 IU/kg/wk) for 52 weeks
Number of subjects: 0
Study 21071558 — intervention group
Group type: COMPARATOR
Intervention: No EPO therapy (control group)
Number of subjects: 0
Study 18536953 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 280 mg once-weekly oral buffered solution (OW OBS)
Number of subjects: 63
Study 18536953 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 40 mg/day tablet
Number of subjects: 63
Study 16622266 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CDDP)
Number of subjects: 115
Study 16622266 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 115
Study 11797178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (group A)
Number of subjects: 77
Study 11797178 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (group B)
Number of subjects: 77
Study 11797178 — intervention group
Group type: COMPARATOR
Intervention: Protease Inhibitor (group C)
Number of subjects: 77
Study 11104404 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin infusion
Number of subjects: 20
Study 11104404 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study 8643963 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin
Number of subjects: 0
Study 8643963 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin
Number of subjects: 0
Study 2090619 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 0
Study 2090619 — intervention group
Group type: COMPARATOR
Intervention: Methadone treatment
Number of subjects: 0
Study 6256579 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids
Number of subjects: 53
Study 6256579 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 53
Study 30354751 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractory Hypertension (RfH)
Number of subjects: 229
Study 30354751 — intervention group
Group type: COMPARATOR
Intervention: Resistant Hypertension (RH)
Number of subjects: 229
Study 28490349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) intervention consisting of one 60-minute session and seven 30-minute telephone/Skype sessions over an eight-week period.
Number of subjects: 0
Study 28490349 — intervention group
Group type: COMPARATOR
Intervention: Fatigue information sheet to use without therapist help (Control group).
Number of subjects: 0
Study 28490349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) intervention
Number of subjects: 0
Study 26265979 — intervention group
Group type: EXPERIMENTAL
Intervention: Insured patients requesting appointments
Number of subjects: 380
Study 26265979 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninsured patients able to pay upfront (>$100) requesting appointments
Number of subjects: 380
Study 26265979 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninsured patients requesting appointments
Number of subjects: 380
Study 26265979 — intervention group
Group type: COMPARATOR
Intervention: Patients requesting appointments from clinics located farther than 30 miles from an ED
Number of subjects: 380
Study 26265979 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients requesting appointments from clinics located within 30 miles of an UC
Number of subjects: 380
Study 23698243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection (0.5 mL dexamethasone suspension and 3 mL lidocaine)
Number of subjects: 92
Study 23698243 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided injection (0.5 mL dexamethasone suspension and 3 mL lidocaine)
Number of subjects: 92
Study 21347765 — intervention group
Group type: EXPERIMENTAL
Intervention: TigerKids program
Number of subjects: 2658
Study 19052293 — intervention group
Group type: EXPERIMENTAL
Intervention: ivermectin (ivc)
Number of subjects: 834
Study 19052293 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole (alb)
Number of subjects: 834
Study 19052293 — intervention group
Group type: EXPERIMENTAL
Intervention: combination (comb)
Number of subjects: 834
Study 19052293 — intervention group
Group type: COMPARATOR
Intervention: reference group (ref)
Number of subjects: 834
Study 16603345 — intervention group
Group type: EXPERIMENTAL
Intervention: MALDI-TOF serum protein profiling
Number of subjects: 116
Study 16603345 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 116
Study 14964327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound field FM amplification (SFA) in treatment group classrooms
Number of subjects: 14
Study 14964327 — intervention group
Group type: COMPARATOR
Intervention: No sound field FM amplification in control group classrooms
Number of subjects: 14
Study 14964327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound field FM amplification (SFA)
Number of subjects: 14
Study 14964327 — intervention group
Group type: COMPARATOR
Intervention: No sound field FM amplification
Number of subjects: 14
Study 10194143 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms fenoterol‐80 micrograms ipratropium bromide (four puffs) from a metered‐dose inhaler (MDI)
Number of subjects: 18
Study 10194143 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg fenoterol‐500 micrograms ipratropium bromide in 5 ml saline from a nebulizer (NEB)
Number of subjects: 18
Study 7779724 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide, methotrexate, fluorouracil)
Number of subjects: 220
Study 7779724 — intervention group
Group type: COMPARATOR
Intervention: CMF/EV (epirubicin, vincristine)
Number of subjects: 220
Study 2181040 — intervention group
Group type: EXPERIMENTAL
Intervention: Various combinations of existing antileprosy drugs administered for 5 years to new untreated patients (Group I) and relapsed patients (Group II)
Number of subjects: 0
Study 2181040 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine (even in low doses)
Number of subjects: 0
Study 2181040 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug regimen effective against both new and relapsed cases of lepromatous leprosy
Number of subjects: 0
Study 386912 — intervention group
Group type: EXPERIMENTAL
Intervention: ephedrine + theophylline + hydroxyzine
Number of subjects: 11
Study 386912 — intervention group
Group type: EXPERIMENTAL
Intervention: ephedrine + theophylline
Number of subjects: 11
Study 386912 — intervention group
Group type: EXPERIMENTAL
Intervention: ephedrine + hydroxyzine
Number of subjects: 11
Study 386912 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 31253441 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4983
Study 31253441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4983
Study 31253441 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 4983
Study 31253441 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis (baseline Lp(a) ≥50 mg/dL)
Number of subjects: 4983
Study 27392954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadmium (Cd) exposure
Number of subjects: 120
Study 27392954 — intervention group
Group type: EXPERIMENTAL
Intervention: High Molybdenum (HMo) exposure
Number of subjects: 120
Study 27392954 — intervention group
Group type: EXPERIMENTAL
Intervention: High Molybdenum (HMo) + Cadmium (Cd) exposure
Number of subjects: 120
Study 27392954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exposure)
Number of subjects: 120
Study 27760066 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 140
Study 27760066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 24210570 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin 0.4 mg
Number of subjects: 150
Study 24210570 — intervention group
Group type: EXPERIMENTAL
Intervention: alfuzosin 10 mg
Number of subjects: 150
Study 24210570 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 150
Study 21960156 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg levobupivacaine in 60 mL 0.9% saline
Number of subjects: 91
Study 21960156 — intervention group
Group type: COMPARATOR
Intervention: 60 mL 0.9% saline (placebo)
Number of subjects: 91
Study 18996767 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-s vagal blocking algorithm
Number of subjects: 27
Study 18996767 — intervention group
Group type: COMPARATOR
Intervention: First-generation device with variable algorithm durations
Number of subjects: 27
Study 17466722 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy (30 minutes per day, 5 days a week for 4 weeks)
Number of subjects: 40
Study 17466722 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 40
Study 15860867 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia (HT) combined with radiotherapy
Number of subjects: 122
Study 15860867 — intervention group
Group type: COMPARATOR
Intervention: No additional Hyperthermia (no-HT)
Number of subjects: 122
Study 12475834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg/d
Number of subjects: 36
Study 12475834 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 100 microg/d
Number of subjects: 36
Study 12475834 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 2000 microg/d
Number of subjects: 36
Study 9787543 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial oral rinse (0.12 percent chlorhexidine)
Number of subjects: 0
Study 9787543 — intervention group
Group type: COMPARATOR
Intervention: No rinse
Number of subjects: 0
Study 8584299 — intervention group
Group type: EXPERIMENTAL
Intervention: RGO‐II hybrid orthosis
Number of subjects: 26
Study 8584299 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme
Number of subjects: 26
Study 29433063 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs and tandospirone
Number of subjects: 245
Study 29433063 — intervention group
Group type: COMPARATOR
Intervention: SSRIs alone
Number of subjects: 245
Study 28767524 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (60 min of treadmill running at 70% V˙O2peak)
Number of subjects: 7
Study 28767524 — intervention group
Group type: COMPARATOR
Intervention: Rest (no exercise)
Number of subjects: 7
Study 26233628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery with blue-blocking intraocular lens (IOL)
Number of subjects: 76
Study 26233628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery with neutral intraocular lens (IOL)
Number of subjects: 76
Study 26233628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 76
Study 24216040 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal education programme
Number of subjects: 0
Study 24216040 — intervention group
Group type: COMPARATOR
Intervention: No antenatal education programme (Control)
Number of subjects: 0
Study 21345770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cerebral regional oxygen saturation (rSO2) monitoring with active display (n = 28)
Number of subjects: 57
Study 21345770 — intervention group
Group type: COMPARATOR
Intervention: Control group (blinded rSO2 monitoring, n = 29)
Number of subjects: 57
Study 19855209 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lateral rotational therapy
Number of subjects: 0
Study 19855209 — intervention group
Group type: COMPARATOR
Intervention: Control group (retrospectively identified subjects)
Number of subjects: 0
Study 16970227 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery in July and August
Number of subjects: 737
Study 16970227 — intervention group
Group type: COMPARATOR
Intervention: Surgery during the rest of the year (September to June)
Number of subjects: 737
Study 16970227 — intervention group
Group type: EXPERIMENTAL
Intervention: All shunt procedures
Number of subjects: 737
Study 15682349 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir plus lamivudine (ABC+3TC)
Number of subjects: 182
Study 15682349 — intervention group
Group type: COMPARATOR
Intervention: Didanosine plus stavudine (ddI+d4T)
Number of subjects: 182
Study 11737740 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose nebulized albuterol therapy (0.15 mg/kg)
Number of subjects: 43
Study 11737740 — intervention group
Group type: COMPARATOR
Intervention: Low dose nebulized albuterol (0.075 mg/kg) plus nebulized ipratropium bromide therapy (250 microg/dose)
Number of subjects: 43
Study 9422890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (20 mg test dose, 30 mg main dose, 25 mg top-up)
Number of subjects: 2
Study 9422890 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (20 mg test dose, 30 mg main dose, 25 mg top-up)
Number of subjects: 2
Study 9422890 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine and Bupivacaine
Number of subjects: 2
Study 12959320 — intervention group
Group type: EXPERIMENTAL
Intervention: Minaprine 100 mg
Number of subjects: 18
Study 12959320 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 25 mg
Number of subjects: 18
Study 12959320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2827471 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg BID)
Number of subjects: 29
Study 2827471 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril plus sulindac (200 mg BID)
Number of subjects: 29
Study 2827471 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril plus indomethacin (50 mg BID)
Number of subjects: 29
Study 2827471 — intervention group
Group type: COMPARATOR
Intervention: Enalapril alone
Number of subjects: 29
Study 28082323 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation ENDS vape pen cue
Number of subjects: 108
Study 28082323 — intervention group
Group type: COMPARATOR
Intervention: Traditional combustible cigarette smoking cue
Number of subjects: 108
Study 27483312 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet score assessing adherence to dietary recommendations
Number of subjects: 472
Study 25015066 — intervention group
Group type: EXPERIMENTAL
Intervention: Late remote ischemic preconditioning (L‐RIPC)
Number of subjects: 200
Study 25015066 — intervention group
Group type: COMPARATOR
Intervention: Control (uninflated cuff)
Number of subjects: 200
Study 23194941 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 200
Study 23194941 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal balloon angioplasty (PTA)
Number of subjects: 200
Study 21095266 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0
Study 21095266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17971112 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD preparation restored with composite resin (Z‐250, 3M ESPE)
Number of subjects: 50
Study 17971112 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD preparation and endodontic treatment
Number of subjects: 50
Study 17971112 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD preparation, endodontic treatment, and composite resin restoration
Number of subjects: 50
Study 17971112 — intervention group
Group type: COMPARATOR
Intervention: Intact teeth (control)
Number of subjects: 50
Study 17971112 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD preparation
Number of subjects: 50
Study 15957693 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.0 mg glucose-free bupivacaine with added fentanyl 20 microg (group BF)
Number of subjects: 40
Study 15957693 — intervention group
Group type: COMPARATOR
Intervention: 11.0 mg glucose-free bupivacaine alone (group B)
Number of subjects: 40
Study 12902533 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX) group
Number of subjects: 31
Study 12902533 — intervention group
Group type: COMPARATOR
Intervention: Control (CO) group
Number of subjects: 31
Study 10367599 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion
Number of subjects: 36
Study 10367599 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 36
Study 7564346 — intervention group
Group type: EXPERIMENTAL
Intervention: UP269-6 (doses ranging from 5 to 180 mg)
Number of subjects: 16
Study 7564346 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 mg)
Number of subjects: 16
Study 7564346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7564346 — intervention group
Group type: EXPERIMENTAL
Intervention: UP269-6 (20 mg and 40 mg)
Number of subjects: 16
Study 7564346 — intervention group
Group type: EXPERIMENTAL
Intervention: UP269-6
Number of subjects: 16
Study 1767900 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick layer of lignocaine-prilocaine cream (2.0 ml)
Number of subjects: 100
Study 1767900 — intervention group
Group type: COMPARATOR
Intervention: Thin layer of lignocaine-prilocaine cream (0.5 ml)
Number of subjects: 100
Study 6951009 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie dietary supplement providing a minimum of 50% of energy requirements
Number of subjects: 24
Study 6951009 — intervention group
Group type: COMPARATOR
Intervention: Blenderized foods only (Control)
Number of subjects: 24
Study 30638880 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention via mobile Jump2Health website, Facebook posts, and text messages
Number of subjects: 30
Study 28411244 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DESs) with paclitaxel
Number of subjects: 139
Study 28411244 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty with bailout Bare Metal Stent (PTA-BMS)
Number of subjects: 139
Study 27143273 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 27143273 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 10
Study 24778230 — intervention group
Group type: EXPERIMENTAL
Intervention: Early success bestowed upon arbitrarily selected recipients
Number of subjects: 0
Study 24778230 — intervention group
Group type: COMPARATOR
Intervention: Control group of nonrecipients
Number of subjects: 0
Study 22433279 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir 400 mg orally twice daily
Number of subjects: 440
Study 22433279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 19727537 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium ER 60 mg once daily for 12 weeks
Number of subjects: 989
Study 19727537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 989
Study 17499082 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Expression (EE)
Number of subjects: 82
Study 17499082 — intervention group
Group type: COMPARATOR
Intervention: Insight and Cognitive Assimilation
Number of subjects: 82
Study 17499082 — intervention group
Group type: COMPARATOR
Intervention: Control Condition
Number of subjects: 82
Study 15562127 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic load diet
Number of subjects: 39
Study 11168503 — intervention group
Group type: COMPARATOR
Intervention: MP/IFN-alpha
Number of subjects: 89
Study 11168503 — intervention group
Group type: EXPERIMENTAL
Intervention: VBMCP/IFN-alpha
Number of subjects: 89
Study 9624241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer patients with microalbuminuria
Number of subjects: 102